✦ LIBER ✦

Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3

✍ Scribed by J. Powis; K. M. Peltekian; S. S. Lee; M. Sherman; V. G. Bain; C. Cooper; M. Krajden; M. Deschenes; R. F. Balshaw; E. Jenny Heathcote; E. M. Yoshida; for the Canadian Pegasys Study Group

Book ID: 108886044
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 124 KB
Volume: 0
Category: Article
ISSN: 1352-0504
DOI: 10.1111/j.1365-2893.2007.00889.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Early virologic response after peginterf

Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C

✍ A. M. Di Bisceglie; R. H. Ghalib; F. M. Hamzeh; V. K. Rustgi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 547 KB

Predicting sustained virological respons

Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin

✍ Eric Snoeck; Janet R. Wade; Frank Duff; Matthew Lamb; Karin Jorga 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 739 KB

Efficacy and safety of peginterferon alp

Efficacy and safety of peginterferon alpha-2a/ribavirin in treatment-naive Cameroonian patients with chronic hepatitis C

✍ Richard Njouom; Michèle Tagni Sartre; Isabelle Timba; Eric Nerrienet; Patrice Tc 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 1 views

## Abstract Data were examined from a day‐to‐day clinical practice in Yaounde, Cameroon to evaluate the efficacy and safety of peginterferon alfa‐2a and ribavirin in treatment‐naive Cameroonian patients with chronic hepatitis C. Ninety adults with chronic hepatitis C (mean age, 53 ± 8 years; 79% ma

Impact of IL28B on treatment outcome in

Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin

✍ Thomas-Matthias Scherzer; Albert Friedrich Stättermayer; Michael Strasser; Herma 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 502 KB

The IL28B genotype is the most important pretreatment predictor of treatment outcome in patients with chronic hepatitis C. The impact of the rs12979860 genotype on relapse was retrospectively evaluated in genotype 1/4 patients who received response-guided therapy with peginterferon alpha-2a 180 μg/w

Response to pegylated interferon alfa-2a

Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4

✍ Hesham El Makhzangy; Gamal Esmat; Mohamed Said; Maissa ElRaziky; Soheir Shouman; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

## Abstract The safety and efficacy of pegylated interferon (PEG‐IFN) alfa‐2a and ribavirin were studied among patients treated for genotype 4 chronic hepatitis C. Ninety‐five patients with chronic hepatitis C genotype 4 were treated with PEG‐IFN alfa‐2a (180 µg/week) plus ribavirin (≥11 mg/kg/day)

Efficacy and safety of peginterferon alf

Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

✍ Savino Bruno; Mitchell L. Shiffman; Stuart K. Roberts; Edward J. Gane; Diethelm 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 500 KB 👁 1 views

The objective of this study is to determine the efficacy and safety of peginterferon alfa-2a (40 KD)/ribavirin in patients with advanced fibrosis. Data from 341 genotype 1/4 patients (99 with bridging fibrosis/cirrhosis) treated for 48 weeks and 1547 genotype 2/3 patients (380 with bridging fibrosis